CommercialCoverageMedium impact
06.02.49b, VeriStrat® Testing for Targeted Therapy in Non-Small Cell Lung Cancer
Independence Blue Cross·Oncology, Pulmonology·Pharmacy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has reissued policy 06.02.49b regarding VeriStrat® Testing for Targeted Therapy in Non-Small Cell Lung Cancer under their Commercial pharmacy policies. This is a reissue of an existing policy with an effective date of March 4, 2026.
Action Required
Before March 4, 2026: Review updated policy 06.02.49b for VeriStrat® Testing coverage requirements and billing guidelines for non-small cell lung cancer patients. Oncology providers and billing team should verify current prior authorization requirements and coverage criteria remain unchanged from previous version.